An Observational Study of Menopausal Symptom in Patients With Gynecological Malignancy After Oophorectomy

Condition(s) studied

Investigational drug(s) / intervention(s)

No intervention: This is an observational study and did not involve interventions.

Study summary

Through long-term dynamic monitoring of gynecologic malignant tumor patients undergoing early menopause after ovaries resection in our center, we explored the changes in menopausal symptoms and bone health status of this population, and studied the effects of platinum combined chemotherapy drugs on menopausal symptoms and bone loss in gynecologic malignant tumor patients. To find the optimal time point and effective regimen for MHT in gynecologic malignancies undergoing surgical menopause, and to provide guidance for osteoporosis screening and prevention strategies in women with gynecologic cancer.

Eligibility

Primary outcome measure(s)

• Bone mineral density — Bone mineral density was followed up at 1, 2, 3, 6, 9, 12, 24 and 36 months after the operation
  Bone density examination
• KMI — The scale was evaluated at 1, 3, 6 and 12 months after surgery.
  Modified Kupperman Index（0-63score）
• MENQOL — The scale was evaluated at 1, 3, 6 and 12 months after surgery.
  Menopause-Specific Quality of Life（0-174score）
• HADS — The scale was evaluated at 1, 3, 6 and 12 months after surgery.
  Hospital Anxiety and Depression Scale（0-21score）
• IOF — The scale was evaluated at 1, 3, 6 and 12 months after surgery.
  Osteoporosis Risk one-minute Test Scale (Yes or No)
• PSQI — The scale was evaluated at 1, 3, 6 and 12 months after surgery.
  Pittsburgh sleep quality index（0-21score）

Trial sites (1)

More Anhui Provincial Hospital trials in China

Other trials for the same condition